Evaluation of differences between human immunodeficiency virus (HIV)-infected men and women in antiretroviral therapy (ART) enrollment characteristics and outcomes might identify opportunities to improve ART program patient outcomes and prevention impact. During September 2008--February 2012, retrospective cohort studies to estimate attrition of enrollees (i.e., from death, stopping ART, or loss to follow-up) at 6-month intervals after ART initiation were completed among samples of adult men and women (defined as aged ≥15 years or aged ≥18 years) who initiated ART during 2004--2010 in six African countries: Côte d'Ivoire in western Africa; Swaziland, Mozambique, and Zambia in southern Africa; and Uganda and Tanzania in eastern Africa. Records for 13,175 ART enrollees were analyzed; sample sizes among the six countries ranged from 1,457 to 3,682. In each country, women comprised 61%--67% of ART enrollees. Median CD4 count range was 119--141 cells/*μ*L for men and 137--161 cells/*μ*L for women. Compared with women, a greater percentage of men initiated ART who had World Health Organization (WHO) HIV stage IV disease. In cohorts from western Africa and southern Africa, the risk for attrition was 15%--26% lower among women compared with men in multivariable analysis. However, in eastern Africa, differences between men and women in risk for attrition were not statistically significant. Research to identify country-specific causes for increased attrition and delayed initiation of care among men could identify strategies to improve ART program outcomes among men, which might contribute to prevention of new HIV infections in female partners.

In each of the six countries, a representative sample of ART facilities was selected. To keep the studies feasible, small facilities were excluded from the sample frames of countries with \>100 ART facilities at the time of sampling. Therefore, in Côte d'Ivoire and Mozambique, facilities that had enrolled \<50 adults on ART were excluded, whereas in Zambia, Uganda, and Tanzania, facilities that had enrolled \<300 adults on ART were excluded ([Table 1](#t1-945-952){ref-type="table"}).

From the eligible number of facilities in Côte d'Ivoire (78), Swaziland (31), and Mozambique (94), totals of 34, 16, and 30 study facilities, respectively, were randomly selected using probability-proportional-to-size sampling ([Table 1](#t1-945-952){ref-type="table"}). From the eligible number of facilities in Zambia (129), Uganda (114), and Tanzania (85), six study facilities were purposefully (nonrandomly) selected in each country to represent different types of ART facilities.

At each selected facility, a sample frame of study-eligible ART patients was created, and simple random sampling used to select the desired sample size of patient medical records. Eligibility criteria included having started ART during 2004--2010 and ≥6 months before data abstraction. Data were abstracted by trained study personnel from ART medical records onto standardized abstraction forms.

Attrition was the primary outcome of interest. A patient was considered lost to attrition if the record showed 1) the patient had died, 2) the patient had stopped ART because of a personal or clinician decision, or 3) the patient had not attended the facility in the 90 days preceding data abstraction for either medication refill or a clinician visit, in which case the patient was considered lost to follow-up.

Variables routinely collected on Ministry of Health medical records at ART initiation including sex, age, CD4 count, WHO HIV disease stage, and ART regimen, were entered into standardized abstraction forms. Data were analyzed using statistical software, and study design was controlled for during analysis. Data for Côte d'Ivoire, Swaziland, and Mozambique were weighted to account for the probability-proportional-to-size sampling.

To estimate the effect of sex on attrition, Cox proportional hazards regression models were used to estimate unadjusted and adjusted hazard ratios, 95% confidence intervals, and p-values. Multivariate models included only cases with complete data for sex, age, CD4 count, WHO HIV disease stage, and ART regimen. The proportional hazards assumption was assessed using visual methods and the Grambsch and Therneu test ([@b1-945-952]). For all countries, a shared frailty model was used to account for intrafacility correlation. Chi-square tests were used to compare distributions of categorical variables, and t-tests were used to compare distributions of continuous variables between men and women. Attrition at 6-month intervals after ART initiation was analyzed using the Kaplan-Meier product-limit estimate of the survivor function.

The sample sizes in the six countries ranged from 1,457 to 3,682, with a total of 13,175 records analyzed ([Table 2](#t2-945-952){ref-type="table"}). In each country, 61%--67% of ART enrollees were women. In each country, men were significantly older than women at ART initiation. Median age range for men was 37--40 years, and for women was 32--35 years.

Compared with women, median CD4 count at ART initiation was significantly lower among men in Côte d'Ivoire (119/*μ*L compared with 155/*μ*L), Swaziland (121/*μ*L compared with 161/*μ*L), and Uganda (128/*μ*L compared with 144/*μ*L). Median CD4 count was lower for men compared with women in Mozambique, Zambia, and Tanzania, although these differences were not statistically significant (p\>0.05).

In all countries, men initiated ART at a more advanced WHO disease stage ([Table 2](#t2-945-952){ref-type="table"}). For example, a higher proportion of men than women initiated ART at WHO stage IV disease in Côte d'Ivoire (26% compared with 21%), Swaziland (18% compared with 10%), Mozambique (20% compared with 13%), Zambia (11% compared with 9%), Uganda (16% compared with 10%), and Tanzania (30% compared with 27%).

For both men and women across all six countries, nevirapine-containing first-line regimens were more common than efavirenz-containing or protease inhibitor--containing regimens, or triple nucleoside reverse transcriptase inhibitor regimens ([Table 2](#t2-945-952){ref-type="table"}). The distribution of first-line ART regimen choices for men differed from choices for women in all countries, with women more likely to be prescribed nevirapine-containing regimens than men ([Table 2](#t2-945-952){ref-type="table"}).

In all countries, point estimates for attrition during the first 4.5 years of ART were lower for women than men ([Table 3](#t3-945-952){ref-type="table"}). This difference was statistically significant in countries in western and southern Africa, where women had 21%--27% lower rates of attrition in unadjusted analysis and 15%--26% lower rates of attrition in adjusted analysis ([Table 3](#t3-945-952){ref-type="table"}). In Uganda and Tanzania, women had 7%--18% lower rates of attrition in unadjusted analysis and 11%--12% lower rates of attrition in adjusted analysis, although the associations between sex and attrition rates were not statistically significant in these two countries.

Editorial Note
==============

Equitable access to ART for both men and women is a principle endorsed by most African governments and international donors, including the U.S. President's Emergency plan for AIDS Relief and the Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria ([@b2-945-952],[@b3-945-952]). However, in Africa, proportionally more HIV-infected women are accessing ART services than men ([@b4-945-952]). Evaluating differences in ART enrollment characteristics and treatment outcomes between men and women might help program managers understand these differences in ART enrollment and identify opportunities for ART program improvement.

This report has two main findings: 1) among representative samples of adult ART enrollees in six African countries, men were more likely than women to initiate ART with advanced HIV disease, and 2) men had higher attrition risk than women after ART initiation. However, differences between men and women in rate of attrition varied by country, being larger and statistically significant in western and southern African cohorts, but smaller and not statistically significant in cohorts from eastern Africa (Uganda and Tanzania).

As in other reports from African ART programs ([@b2-945-952],[@b5-945-952]--[@b7-945-952]), men initiated ART at more advanced HIV disease stages than women. Late initiation of ART among men has commonly been attributed to sex differences in health-seeking behavior, with men considered more likely to delay access to health care for various reasons, including stigma, male norms that discourage admitting ill health, and employment responsibilities ([@b2-945-952]). However, some have proposed that the prioritization of maternal and child health services by global and national public health organizations in Africa has resulted in inequitable access to health services, including ART ([@b2-945-952],[@b3-945-952]). Recent reports suggest that whereas nearly all African countries include initiatives focused on women in their national AIDS strategies, only 10% of countries are effectively engaging men and boys in the national AIDS response ([@b8-945-952]). To address delayed enrollment in ART among men, increased attention from national governments and international donors to identify and implement evidence-based strategies that achieve earlier HIV testing and ART among men might be needed ([@b2-945-952],[@b3-945-952]).

As in other studies from western and southern Africa ([@b2-945-952],[@b5-945-952],[@b6-945-952],[@b9-945-952]), adjusting for possible baseline predictors of ART outcomes, including CD4 count, WHO HIV disease stage, age, and ART regimen, did not fully account for the increased rate of attrition among men in Côte d'Ivoire, Swaziland, Mozambique, and Zambia. This suggests unmeasured factors are contributing to either increased rates of death or loss to follow-up among men ([@b2-945-952]). Some reports have suggested sex differences in health-seeking behavior, biologic differences in response to ART, increased male risk for opportunistic infections, worse adherence to ART pill-taking among men, or background differences in mortality rates by sex in the general population are responsible for higher attrition rates among men taking ART ([@b2-945-952]).

In this analysis, although rates of attrition were marginally higher among men than women in Uganda and Tanzania, the effect of sex on attrition risk was smaller than that observed in cohorts from western and southern Africa. This might indicate variations in the effect of sex on attrition risk by country or region. One possible explanation is that internal and cross-border migration patterns vary by country and region. Historically, cross-border migration for work, which is more common among men than women, varies by region in Africa, being most common in western ([@b10-945-952]) and southern Africa, where South Africa is a hub for migrant labor from surrounding countries ([@b10-945-952]). Further research into variations in the effect of sex on attrition risk by country or region might inform interventions to reduce rates of male attrition.

The findings in this report are subject to at least two limitations. First, missing data for certain covariates of interest at ART initiation might have introduced some measurement error, and might have affected estimates of hazard ratios. Second, because of differences in cohort size, there was greater power to detect differences in outcomes between men and women in Swaziland, Mozambique, and Côte d'Ivoire than in Zambia, Uganda, and Tanzania, which limits ability to make conclusions about country variations in the effect of sex on attrition risk.

Across six countries in Africa, men initiated ART with more advanced disease and had statistically significant higher attrition in western and southern African cohorts. Reasons for differences between men and women in ART enrollment are not fully understood but might include lack of emphasis by donors and national governments on the importance of engaging men early in ART ([@b3-945-952]). Higher attrition rates among men are not fully explained by traditional predictors of poor outcomes (e.g., low CD4 count and advanced WHO HIV disease stage). Identifying and implementing evidence-based interventions to improve male enrollment and retention in ART programs is important to reduce male AIDS-related mortality and might contribute to prevention of new HIV infections in female partners ([@b3-945-952]).

What is already known on this topic?

Evaluating differences between human immunodeficiency virus (HIV)-infected men and women in antiretroviral therapy (ART) enrollment characteristics and treatment outcomes can help program managers understand why proportionally more women than men are accessing ART.

What is added by this report?

This retrospective cohort study of six African countries found lower median CD4 counts and more World Health Organization stage IV HIV disease in men at enrollment in all six countries. In addition, the risk of attrition during ART was significantly higher in men in western and southern African countries, even after controlling for possible baseline predictors of ART outcomes. This finding suggests that unidentified factors are contributing to this higher attrition risk in these countries. In eastern Africa, risk for attrition did not differ significantly between men and women.

What are the implications for public health practice?

Further research on country-specific reasons for differences between HIV-infected men and women in ART enrollment and in attrition while on ART are needed. The results of such studies could potentially identify strategies to improve early diagnosis and treatment among men and improve program outcomes.

###### 

Summary of sampling criteria and methods[\*](#tfn1-945-952){ref-type="table-fn"}[†](#tfn2-945-952){ref-type="table-fn"} used to select adult antiretroviral therapy (ART) enrollees for retrospective cohort studies conducted --- six African countries, 2008--2012

  Characteristic                                          Côte d'Ivoire                            Swaziland                           Mozambique                               Zambia                                          Uganda                                          Tanzania                                        Total
  ------------------------------------------------------- ---------------------------------------- ----------------------------------- ---------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- -------------
  **Stage 1: Selection of study facilities**                                                                                                                                                                                                                                                                                    
   No. of ART clinics                                     124 by Dec 2007                          31 by Dec 2009                      152 by Dec 2006                          322 by Dec 2007                                 286 by Dec 2007                                 210 by Dec 2007                                 
   No. of enrollees at ART clinics                        36,943                                   50,767                              43,295                                   65,383                                          45,946                                          41,920                                          
   Clinic eligibility criteria for study                  Enrolled ≥50 adults on ART by Dec 2007   All ART initiation sites eligible   Enrolled ≥50 adults on ART by Dec 2006   Enrolled ≥300 adults on ART by Dec 2007         Enrolled ≥300 adults on ART by Dec 2007         Enrolled ≥300 adults on ART by Dec 2007         
   No. of study-eligible clinics                          78                                       31                                  94                                       129                                             114                                             85                                              **531**
   Estimated no. of study-eligible enrollees at clinics   36,110                                   50,767                              42,234                                   58,845[§](#tfn3-945-952){ref-type="table-fn"}   41,351[§](#tfn3-945-952){ref-type="table-fn"}   37,728[§](#tfn3-945-952){ref-type="table-fn"}   **267,035**
   No. of clinics selected                                34                                       16                                  30                                       6                                               6                                               6                                               **98**
  **Stage 2: Selection of study patients**                                                                                                                                                                                                                                                                                      
   Age at ART initiation criteria for study enrollees     ≥15 yrs                                  ≥15 yrs                             ≥15 yrs                                  ≥18 yrs                                         ≥18 yrs                                         ≥18 yrs                                         
   Years of ART enrollment                                2004--2007                               2004--2010                          2004--2007                               2004--2009                                      2004--2009                                      2004--2009                                      
   Planned sample size                                    4,000                                    2,500                               2,600                                    1,500                                           1,500                                           1,500                                           **13,600**
   No. of eligible study enrollees                        3,682                                    2,510                               2,596                                    1,457                                           1,472                                           1,458                                           **13,175**
   Date of data collection                                Nov 2009--March 2010                     Nov 2011--Feb 2012                  Sept--Nov 2008                           April--July 2010                                April--July 2010                                April--July 2010                                

In Côte d'Ivoire, Swaziland, and Mozambique, study facilities were randomly selected using probability-proportional-to-size sampling. In Zambia, Uganda, and Tanzania, study facilities were purposefully selected to represent different types of ART facilities in each country.

In all six countries, at each selected facility, a sample frame of study-eligible ART patients was created, and simple random sampling was used to select the desired sample size of patient medical records.

Estimate from available published data.

###### 

Enrollment characteristics of adults (N = 13,175) initiating antiretroviral therapy (ART) --- six African countries, 2004--2010

                                                                          Côte d'Ivoire[\*](#tfn5-945-952){ref-type="table-fn"} (N = 3,682)   Swaziland[\*](#tfn5-945-952){ref-type="table-fn"} (N = 2,510)   Mozambique[\*](#tfn5-945-952){ref-type="table-fn"} (N = 2,596)   Zambia[†](#tfn6-945-952){ref-type="table-fn"} (N = 1,457)   Uganda[†](#tfn6-945-952){ref-type="table-fn"} (N = 1,472)   Tanzania[†](#tfn6-945-952){ref-type="table-fn"} (N = 1,458)                                                                                                                                                         
  ----------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- --------- ---------------- ------------- --------- ---------------- ------------- --------- ---------------- ------------- --------- ---------------- -------------
  **Sex, no., and median age**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Women                                                                  2,422                                                               34                                                              \<0.001                                                          1,621                                                       32                                                          \<0.001                                                       1,576     32               \<0.001       880       34               \<0.001       964       34               \<0.001       973       35               \<0.001
   Men                                                                    1,260                                                               40                                                                                                                               889                                                         38                                                                                                                        1,020     38                             575       37                             502       37                             484       39               
                                                                          **No.**                                                             **Median CD4**                                                  **p-value**                                                      **No.**                                                     **Median CD4**                                              **p-value**                                                   **No.**   **Median CD4**   **p-value**   **No.**   **Median CD4**   **p-value**   **No.**   **Median CD4**   **p-value**   **No.**   **Median CD4**   **p-value**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Sex, no., and median CD4 count at ART initiation (cells/***μ***L)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Women                                                                  1,811                                                               155                                                             \<0.001                                                          1,487                                                       161                                                         \<0.001                                                       1,373     161              0.063         639       139              0.261         774       144              0.012         742       137              0.232
   Men                                                                    935                                                                 119                                                                                                                              809                                                         121                                                                                                                       881       141                            411       127                            395       128                            379       121              
   Missing data                                                           936                                                                 ---                                                                                                                              214                                                         ---                                                                                                                       342       ---                            407       ---                            303       ---                            337       ---              
                                                                          **No.**                                                             **(%)**                                                         **p-value**                                                      **No.**                                                     **(%)**                                                     **p-value**                                                   **No.**   **(%)**          **p-value**   **No.**   **(%)**          **p-value**   **No.**   **(%)**          **p-value**   **No.**   **(%)**          **p-value**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Sex, no., and %**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   Women                                                                  2,422                                                               \(67\)                                                                                                                           1,621                                                       \(65\)                                                                                                                    1,576     \(62\)                         882       \(61\)                         968       \(66\)                         974       \(67\)           
   Men                                                                    1,260                                                               \(33\)                                                                                                                           889                                                         \(35\)                                                                                                                    1,020     \(38\)                         575       \(39\)                         504       \(34\)                         484       \(33\)           
  **WHO HIV disease stage**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Stage I/II                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    Women                                                                 363                                                                 \(19\)                                                          0.064                                                            700                                                         \(50\)                                                      \<0.001                                                       386       \(39\)           0.001         326       \(41\)           0.029         434       \(51\)           0.006         225       \(29\)           0.006
    Men                                                                   224                                                                 \(22\)                                                                                                                           260                                                         \(34\)                                                                                                                    233       \(34\)                         170       \(34\)                         205       \(45\)                         76        \(20\)           
   Stage III                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    Women                                                                 987                                                                 \(61\)                                                                                                                           590                                                         \(40\)                                                                                                                    451       \(48\)                         390       \(49\)                         330       \(39\)                         347       \(44\)           
    Men                                                                   453                                                                 \(53\)                                                                                                                           377                                                         \(48\)                                                                                                                    288       \(46\)                         277       \(55\)                         178       \(39\)                         192       \(50\)           
   Stage IV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    Women                                                                 331                                                                 \(21\)                                                                                                                           149                                                         \(10\)                                                                                                                    136       \(13\)                         73        \(9\)                          87        \(10\)                         212       \(27\)           
    Men                                                                   223                                                                 \(26\)                                                                                                                           144                                                         \(18\)                                                                                                                    123       \(20\)                         54        \(11\)                         73        \(16\)                         113       \(30\)           
   Missing data                                                           1,101                                                               \(30\)                                                                                                                           290                                                         \(12\)                                                                                                                    979       \(38\)                         167       \(11\)                         165       \(11\)                         293       \(20\)           
  **Female regimens**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   NVP-3TC-D4T/AZT/TDF                                                    1,219                                                               \(49\)                                                          0.077                                                            1,153                                                       \(72\)                                                      \<0.001                                                       1,430     \(91\)           \<0.001       606       \(69\)           \<0.001       772       \(80\)           0.013         760       \(78\)           0.088
   EFV-3TC-D4T/AZT/TDF                                                    692                                                                 \(30\)                                                                                                                           372                                                         \(23\)                                                                                                                    124       \(8\)                          260       \(29\)                         179       \(18\)                         201       \(21\)           
   Triple NRTI                                                            90                                                                  \(3\)                                                                                                                            0                                                           ---                                                                                                                       13        \(1\)                          0         ---                            3         (\<1)                          0         ---              
   PI-based                                                               122                                                                 \(4\)                                                                                                                            0                                                           ---                                                                                                                       1         (\<1)                          6         \(1\)                          8         \(1\)                          0         ---              
   Unknown                                                                211                                                                 \(10\)                                                                                                                           96                                                          \(5\)                                                                                                                     8         (\<1)                          0         ---                            0         ---                            0         ---              
   Other                                                                  88                                                                  \(5\)                                                                                                                            0                                                           ---                                                                                                                       0         ---                            10        \(1\)                          6         \(1\)                          13        \(1\)            
  **Male regimens**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   NVP-3TC-D4T/AZT/TDF                                                    548                                                                 \(42\)                                                                                                                           519                                                         \(59\)                                                                                                                    881       \(85\)                         334       \(58\)                         362       \(72\)                         357       \(74\)           
   EFV-3TC-D4T/AZT/TDF                                                    430                                                                 \(36\)                                                                                                                           309                                                         \(35\)                                                                                                                    120       \(13\)                         225       \(39\)                         133       \(26\)                         122       \(25\)           
   Triple NRTI                                                            48                                                                  \(3\)                                                                                                                            0                                                           ---                                                                                                                       4         (\<1)                          0         ---                            1         (\<1)                          0         ---              
   PI-based                                                               84                                                                  \(6\)                                                                                                                            1                                                           (\<1)                                                                                                                     2         (\<1)                          9         \(2\)                          5         \(1\)                          1         (\<1)            
   Unknown                                                                110                                                                 \(9\)                                                                                                                            60                                                          \(6\)                                                                                                                     13        \(1\)                          0         ---                            0         ---                            0         ---              
   Other                                                                  40                                                                  \(3\)                                                                                                                            0                                                           ---                                                                                                                       0         ---                            7         \(1\)                          3         (\<1)                          974       \(1\)            

**Abbreviations:** WHO = World Health Organization; NVP = nevirapine; EFV = efavirenz; 3TC = lamivudine; D4T = stavudine; AZT = zidovudine; TDF = tenofovir; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.

Data for Côte d'Ivoire, Swaziland, and Mozambique are weighted to account for the sampling method.

Data were missing for two enrollees in Zambia, six in Uganda, and one in Tanzania.

p-value for comparison of ART enrollee characteristics for men and women (t-test for continuous variables and chi-square test for categorical variables).

###### 

Percentage of antiretroviral therapy (ART) enrollees alive and on therapy, by years after ART initiation, and attrition[\*](#tfn9-945-952){ref-type="table-fn"} rate and risk for attrition, by sex --- retrospective cohort studies, six African countries

                                                                            Côte d'Ivoire              Swaziland      Mozambique    Zambia                     Uganda         Tanzania                                                                                                                                                                                                                        
  ------------------------------------------------------------------------- -------------------------- -------------- ------------- -------------------------- -------------- ------------- -------------------------- -------------- ------------- -------------------------- -------------- ------------- -------------------------- -------------- ------------- -------------------------- -------------- -------------
  0.5                                                                       81                         75                           86                         81                           84                         81                           81                         75                           94                         91                           76                         75             
  1                                                                         76                         70                           82                         77                           78                         73                           77                         69                           90                         88                           71                         67             
  1.5                                                                       72                         66                           79                         74                           74                         69                           73                         65                           87                         84                           65                         62             
  2                                                                         67                         60                           76                         71                           71                         66                           70                         60                           85                         81                           62                         59             
  2.5                                                                       63                         55                           74                         68                           69                         64                           66                         57                           82                         78                           58                         57             
  3                                                                         59                         51                           71                         64                           68                         59                           63                         54                           78                         76                           57                         55             
  3.5                                                                       56                         48                           71                         63                           65                         53                           61                         51                           77                         74                           52                         52             
  4                                                                         51                         43                           68                         62                           65                         52                           57                         49                           75                         73                           49                         50             
  4.5                                                                       47                         40                           65                         62                           62                         52                           55                         47                           73                         71                           48                         44             
  **Attrition rate**                                                        **Per 100 person-years**   **(95% CI)**                 **Per 100 person-years**   **(95% CI)**                 **Per 100 person-years**   **(95% CI)**                 **Per 100 person-years**   **(95% CI)**                 **Per 100 person-years**   **(95% CI)**                 **Per 100 person-years**   **(95% CI)**   
                                                                                                                                                                                                                                                                                                                                                                                                              
  Sex                                                                                                                                                                                                                                                                                                                                                                                                         
   Men                                                                      24.7                       (22.4--27.2)                 16.2                       (14.4--18.2)                 23.0                       (19.8--26.9)                 22.9                       (20.3--25.9)                 9.9                        (8.2--11.9)                  25.5                       (22.2--29.2)   
   Women                                                                    18.7                       (17.4--20.2)                 12.4                       (11.3--13.6)                 17.9                       (15.7--20.4)                 16.2                       (14.5--18.1)                 7.9                        (6.8--9.1)                   24.0                       (21.7--26.6)   
  **Unadjusted risk for attrition**                                         **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**
                                                                                                                                                                                                                                                                                                                                                                                                              
  Sex                                                                                                                                                                                                                                                                                                                                                                                                         
   Men                                                                      Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---            
   Women                                                                    0.78                       (0.70--0.86)   \<0.001       0.78                       (0.68--0.90)   0.002         0.79                       (0.71--0.88)   \<0.001       0.73                       (0.62--0.86)   \<0.001       0.82                       (0.65--1.03)   0.091         0.93                       (0.78--1.10)   0.406
  **Adjusted risk for attrition**[†](#tfn10-945-952){ref-type="table-fn"}   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**   **HR**                     **(95% CI)**   **p-value**
                                                                                                                                                                                                                                                                                                                                                                                                              
  Sex                                                                                                                                                                                                                                                                                                                                                                                                         
   Men                                                                      Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---                          Referent                   ---            
   Women                                                                    0.74                       (0.65--0.83)   \<0.001       0.85                       (0.74--0.97)   0.021         0.79                       (0.70--0.89)   \<0.001       0.82                       (0.65--1.02)   0.079         0.88                       (0.66--1.18)   0.407         0.89                       (0.71--1.12)   0.311

**Abbreviations:** CI = confidence interval; HR = hazard ratio.

From death, stopping ART, or loss to follow-up.

Multivariate analysis included only complete cases: Côte d'Ivoire (2,394), Swaziland (2,090), Mozambique (1,426), Zambia (972), Uganda (1,056), and Tanzania (938). In addition to sex, multivariate analysis adjusted for the following characteristics at ART initiation: age, CD4 count, World Health Organization HIV disease stage, and treatment regimen.
